MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.

NCT Number	NCT06130046
Lead Sponsor	University of Rome Tor Vergata
Conditions	Kidney Transplant; Complications, Liver Transplant; Complications
Enrollment	300 participants
Start Date	2022-12-01
Primary Completion	2026-05-01 (estimated)
Study Completion	2026-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-01